Dexcom’s 2021 Sales Rise 27 Percent

Dexcom yesterday reported financial results for the fourth quarter and fiscal year 2021.
 
The company’s fourth quarter 2021 sales rose 23 percent to $698.2 million over the prior year. Revenue grew 15 percent in the U.S. and 54 percent internationally. Dexcom indicated volume growth and “strong new customer additions” as the primary drivers for these increases.
 
Full year fiscal 2021 sales ballooned 27 percent over the previous year to reach $2.45 billion. Revenue in the U.S. rose 23 percent and international proceeds increased 44 percent.
 
Dexcom last year submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for review of the Dexcom G7 continuous glucose monitoring (CGM) system. Mean absolute relative difference (MARD) data from Dexcom G7’s clinical trial amounted to an average of 8.2 percent in adults and 8.1 percent in pediatric patients.
 
Last year the American Diabetes Association recognized Dexcom’s MOBILE trial in their updated 2022 Standards of Care to acknowledge real-time CGM’s benefit for people with Type 2 diabetes using basal insulin.
 
“2021 was another great year for Dexcom, producing record customer growth, an expanded product and software portfolio, and further success in our ongoing campaign to improve global access,” Dexcom chairman, president, and CEO Kevin Sayer told the press. “With the upcoming launch of G7 and several exciting initiatives planned for 2022, we look forward to another great year ahead.”